Technological offer

Natural nutraceutical to promote the prevention of the cancer stem cells (CSCs) phenotype acquisition at the origin of tumor regrowth, metastasis and relapse.

Stratum corneum lipid-matrix like liposomes capable of acting as oral mucosa impermeabilization agents to prevent the penetration of viruses or biocides through the mucosa.

New nanostructured lipid carriers have demonstrated inhibition of bacterial biofilm formation. They are useful for treating or preventing chronic infections such as those associated with prosthetic implants and recurrent respiratory infections.

A family of quinolyl nitrone derivatives has been identified as potential agents for the prevention or treatment of hearing loss caused by physical factors, such as noise or exposure to ototoxic substances.

Novel glycolipid mimetics able to express anti-inflammatory or adjuvant activity in a context dependent manner. The compounds can be used for the treatment of immune diseases cursed with Th1/Th2 imbalance or as vaccine adjuvants.

Compounds and its use for the treatment of diseases caused by RNA viruses, such as West Nile virus (WNV), Zika virus (ZIKV), among others.

A new immunotherapy strategy based on the administration of a monoclonal antibody specific for pre-TCR has been developed and validated in a preclinical human T-ALL xenotransplantation model in mice.

Inhibitor of Interferon type I (IFN-I) is capable of inhibiting the inflammatory response in those autoimmune diseases in which this cytokine is involved, called interferonopathies, such as systemic lupus erythematosus and Aicardi-Goutières syndrome.

A new immunotherapy strategy based on the administration of ADCs or CAR-T cells derived from a monoclonal antibody specific for the pre-TCR receptor, which impairs LIC activity and tumor progression, has been developed and validated in a preclinical human T-ALL xenotransplantation model in mice.

Novel compounds based on a repurposed drug to combat gram (+) bacterial infections.